RE:RE:RE:RE:first the haltThe nano emulsion process or something similar is available to most marijuana companies now. It has to do with rapid onset and offset for THC imbibers.
I, too think that medical is a whole other tangent that hasn't been explored nearly enough. After all the US just put some legislation through that marijuana can be transported across State lines legally for studies by them that do that kind of stuff.
Big Pharma has flirted with it which is how we got GW Pharma and Charlottes Web, anti seizure formula, made from CBD from some specific strain that brings that to the table.
There is a whole open field for medical uses, but takes longer to get there with the same kind of hoops that Big Pharma goes through to get their existing drug line classified as such. Lots of analyzing and testing to prove the claims of what it is useful for.
There is a wealth of knowledge out there from cannabinists and some budtenders of strains that customers are finding useful as pharma substitues, mostly for pain, anxiety and sleep primarily and there is potential for weight loss product, energy supplement or glaucoma and whatever else patients have migrated to as an alternative to the pill type medicines that show promise.
Bhang is recognized for its usefulness for CBD chocolate for aches and pains. It hasn't been bona fide approved without all of the scrutiny of the Health Watch agencies that give these things drug classification numbers but I do believe that potpreneurs that really think they are on to something like this will step up and spend the money to do the trials and studies to make that happen.
My due diligence suggests that consumer preference is changing from smokeable skus towards beverage skus for both CBD and THC and there are some pretty big alcohol companies taking note and in concurrence that they might lose marketshare as buzzy little calorie reduced options might cut into their soft alcohol and beer sales.
I don't know if BHANG has what it takes to make it over this hurdle without bringing some active, medical capable expertise on board and I doubt that the current management would be able to raise the money necessary after their dismal performance since ipo'ing.
Waiting is the hardest to see what TRUL hawking our skus through their dispensaries and retailers is going to do for our bottomline.
I have noticed a very disturbing trend of a lot of the junior pot companies being unable to post financials on due dates or give monthly reports on time. That is the first step to a halt or worsel
That is basic management 101 and not good to ignore these necessary components of maintaining a listing.
Is this nefarious with ulterior motive or just the nature of this industry.
Shareholder first in publicly traded companies!